Incidence and implications of chemotherapy related hand-foot syndrome

References

• Baack BR, Burgdorf WHC Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991;24:457–461.
   PubMed Web of Science ®Google Scholar
• Saif MW Capecitabine and hand-foot syndrome. Expert Opin Drug Saf 2011;10:159–169.
   PubMed Web of Science ®Google Scholar
• Lassere Y, Hoff P Management of hand-foot syndrome in patients treated with capecitabine (XELODA). Eur J Oncol Nurs 2004;8 Suppl 1:SS31-S40.
   Google Scholar
• Vilalon G, Martin JM, Pinazon MI, et al. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine. Am J Clin Dermatol 2009;10:261–263.
   PubMed Web of Science ®Google Scholar
• Do JE, Kim YC Capecitabine – induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? Clin Exp Dermatol 2007;32:519–521.
   PubMed Web of Science ®Google Scholar
• Vasudevan B An unusual case of capecitabine hyperpigmentation: is hyperpigmentation a part of hand-foot syndrome or a separate entity? Indian J Pharmacol 2010;42:326–328.
   PubMed Web of Science ®Google Scholar
• Bogenrieder T, Weitzel C, Scholmerich J, et al. Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? Dermatology 2002;205:174–175.
   PubMed Web of Science ®Google Scholar
• Wong M, Choo PS, Tan EH Travel warning with capecitabine. Ann Oncol 2009;20:1281.
   PubMed Web of Science ®Google Scholar
• Disel U, Gürkut O, Abali H, et al. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol 2010;29:140–142.
   PubMed Web of Science ®Google Scholar
• Bolognia JL, Cooper DL, Glusac EJ Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008;59:524–529.
   PubMed Web of Science ®Google Scholar
• Choi JN Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts. Clin Dermatol 2011;29:587–601.
   PubMed Web of Science ®Google Scholar
• Nagore E, Insa A, Sanmartin O Antineoplastic therapy-induced palmar plantar erhthrodysesthesia (‘hand-foot’) syndrome: incidence, recognision and management. Am J Clin Dermatol 2000;1:225–234.
   PubMedGoogle Scholar
• NCI Common Terminology Criteria for Adverse Events (CTCAE) v4. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
   Google Scholar
• Saif MW, Elfiky AA Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. J Support Oncol 2007;7:337–343.
   Google Scholar
• Palaia I, Angioli R, Bellati F, et al. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia. Am J Obstet Gynecol. 2006;195:e1–e2.
   Google Scholar
• Hoesly FJ, Baker SG, Gunawardane ND, et al. Capecitabine-induced hand-foot syndrome complicated by pseudomonal surperinfection resulting in bacterial sepsis and death. Case report and review of the literature. Arch Dermatol 2011;147:1418–1423.
   PubMedGoogle Scholar
• Sibaud V, Dalenc F, Chevreau C, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 2011;16:1469–1478.
   PubMed Web of Science ®Google Scholar
• Chu D, Lacouture ME, Fillos Tet al. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008;47:176–186.
   PubMed Web of Science ®Google Scholar
• Degen A, Alter M, Schenck F, et al. The hand-foot-syndrome associated with medical tumor therapy classification and management. J Dtsch Dermatol Ges 2010;8:652–661.
   PubMed Web of Science ®Google Scholar
• Lipworth AD, Robert C, Zhu AX Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009;77:257–271.
   PubMed Web of Science ®Google Scholar
• Miller KK, Gorcey L, McLellan BN Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014;71:787–794.
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparableefficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440–449.
   PubMed Web of Science ®Google Scholar
• Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998a;16:301–308.
   PubMed Web of Science ®Google Scholar
• Childress J, Lokich J Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol 2003;26:435–436.
   PubMed Web of Science ®Google Scholar
• Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol- coated liposomal doxorubicin. Arch Dermatol 2000;136: 1475–1480.
   PubMed Web of Science ®Google Scholar
• Mrozek-Orlowski ME, Frye DK, Sanborn HM Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999;26: 753–762.
   PubMedGoogle Scholar
• Martschick A, Sehouli J, Patzelt A, et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res 2009;29:2307–2313.
   PubMed Web of Science ®Google Scholar
• Jacobi U, Waibler E, Schulze P et al. Release of doxorubicin in sweat: first step to induce the palmar–plantar erythrodysesthesia syndrome? Ann Oncol 2005;16:1210–1211.
   PubMed Web of Science ®Google Scholar
• Lademann J, Martschick A, Darvin ME, et al. Treatment of patients with chemotherapy-induced PPE using a prevention ointment containing high concentrations of antioxidants. J Clin Oncol 2012;30(suppl):abstr e19558.
   Google Scholar
• Kluschke F, Martschick A, Darvin ME, et al. Application of an ointment with high radical protection factor as a prevention strategy against PPE. J Clin Oncol 2012;30(suppl):abstr 5064.
   Google Scholar
• Yokomichi N, Nagasawa T, Coler-Reilly A, et al. Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin. Hum Cell 2013;26:8–18
   PubMed Web of Science ®Google Scholar
• Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006;12:5491–5495.
   PubMed Web of Science ®Google Scholar
• Saif MW, Seller S, Diasio RB Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is Ethnicity a Risk Factor? JOP 2008;9:226–229.
   Google Scholar
• Caronia D, Martin M, Sastre J et al. A polymorphism in the Cytidine Deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res 2011;17:2006–2013.
   PubMed Web of Science ®Google Scholar
• Colemen RL, Lin WM, Miller DS, et al. Oral dexamethasone (DMS) attenuates doxil-induced palmar plantar erythema (PPE) in patients with recurrent gynecologic malignancies. Proc Am Soc Clin Oncol 2001;20:883 [abstract].
   Google Scholar
• Drake RD, Lin WM, King M, et al. Oral dexamethasone attenuates Doxil-induced palmar– plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 2004;94:320–324.
   PubMed Web of Science ®Google Scholar
• Vukelja SJ, Lombardo FA, James WD, et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989;111:688–689.
   PubMed Web of Science ®Google Scholar
• Denda M, Inoue K, Fuziwara S, et al. P2X purinergic receptor antagonist accelerates skin barrier repair and prevents epidermal hyperplasia induced by skin barrier disruption. J Invest Dermatol 2002;119:1034–1040.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Tajuddin A, Guitart J, et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995;75:2169–2173.
   PubMed Web of Science ®Google Scholar
• Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990;8:57–63.
   PubMed Web of Science ®Google Scholar
• Corrie PG, Bulusu R, Wilson CB, et al. A randomized study evaluating the use of pyridoxine to avoid capecitabien dose modifications. Br J Cancer 2012;107:585–587.
   PubMed Web of Science ®Google Scholar
• Kang YK, Lee SS, Yoon DH, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010;28:3824–3829.
   PubMed Web of Science ®Google Scholar
• Chalermchai T, Tantiphlachiva K, Suwanrusme H, et al. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. Asia-Pacific J Clin Oncol 2010;6:155–160.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhand L, Wang Q, et al. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review. PLOS One 2013;8:e72245.
   Google Scholar
• Vail DM, Chun R, Thamm DH, et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998;4:1567–1571.
   PubMed Web of Science ®Google Scholar
• Lin E, Morris JS, Ayers GD Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology 2002;16(12Suppl No 14): 31–37.
   PubMed Web of Science ®Google Scholar
• Edward LIN, Jeffrey S, Morris JS, et al. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology 2002;16: 31–37.
   Web of Science ®Google Scholar
• Zhang RX, Wu XJ, Wan DS, et al. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 2012;23:1348–1353.
   PubMed Web of Science ®Google Scholar
• Macedo LT, Lima JP, Dos Santos LV, et al. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomized trials. Support Care Cancer 2014;22:1585–1593.
   PubMed Web of Science ®Google Scholar
• MacKay D, Miller AL Nutritional support for wound healing. Altern Med Rev 2003;8:359–377.
   PubMedGoogle Scholar
• Thiele JJ, Hsieh SN, Ekanayake-Mudiyanselage S. Vitamine E: critical review of its current use in cosmetic and clinical dermatology. Dermatol Surg 2005;31:805–813.
   PubMed Web of Science ®Google Scholar
• Tsoureli-Nikita E, Hercogova J, Lotti T, et al. Evaluation of dietary intake of vitamin E in the treatment of atopic dermatitis: a study of the clinical course and evaluation of the immunoglobulin E serum levels. Int J Dermatol 2002;41:146–150.
   PubMed Web of Science ®Google Scholar
• Kara IO, Sahin B, Erkisi M Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006;15:414–424.
   PubMed Web of Science ®Google Scholar
• Yamamoto D, Yamamoto C, Tanaka K. Novel and effective management of capecitabine induced hand foot syndrome. J Clin Oncol 2008;26(13):2214–2215. Abstract 20615.
   PubMed Web of Science ®Google Scholar
• Vakalis D, Ioannides D, Lazaridou E, et al. Acral erythema induced by chemotherapy with cisplatin. Br J Dermatol 1998;139:750–751.
   PubMed Web of Science ®Google Scholar
• Kingsley EC 5-Fluorouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 1994;120:813.
   PubMed Web of Science ®Google Scholar
• Meadows KL, Rushing C, Honeycutt Wet al. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. Support Care Cancer 2015;23:1311–1319.
   PubMed Web of Science ®Google Scholar
• Pendharkar D, Goyal H Novel & effective management of capecitabine induced hand foot syndrome. J Clin Oncol 2004;22:3099–3103.
   PubMed Web of Science ®Google Scholar
• Chin SF, Chen NT, Oza AM et al. Use of ‘Bag Balm’ as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents. Proc Am Soc Clin Oncol 2001;20: 1632a (Abstr).
   Google Scholar
• Lopez AM, Wallace L, Dorr RT, et al. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999;44:303–306.
   PubMed Web of Science ®Google Scholar
• Olver IN, Aisner J, Hament A, et al. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988;6:1732–1735.
   PubMed Web of Science ®Google Scholar
• Ilyas S, Wasif K, Saif MW Topical henna ameliorated capecitabine-induced hand-foot syndrome. Cutan Ocul Toxical 2014;33:253–255.
   PubMed Web of Science ®Google Scholar
• Yucel I, Guzin G Topical henna for capecitabine induced hand-foot syndrome. Invest New Drugs 2008;26:189–192.
   PubMed Web of Science ®Google Scholar
• Holfeinz RD, Gencer D, Schulz H, et al. Mapisal versus urea cream as prophylaxis for Capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO quality of life working group. J Clin Oncol 2015;33:2444–2449.
   PubMed Web of Science ®Google Scholar
• Sakir A. Novel & effective management of capecitabine induced hand foot syndrome. The use of urea ointment. In: Schiff E, editor. ASCO Annual Meeting Proceedings (Post-Meeting Edition). New Orleans: ASCO; 2004. p. 8105.
   Google Scholar
• Wolf SL, Qin R, Menon SP, et al. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 2010;28:5182–5187.
   PubMed Web of Science ®Google Scholar
• Molpus KL, Anderson LB, Craig CL, et al. The effect of regional cooling on toxicities associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 2004;93:513–516.
   PubMed Web of Science ®Google Scholar
• Mangili G, Petrone M, Gentile C, et al. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 2008;108:332–335.
   PubMed Web of Science ®Google Scholar
• Scotte F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008;112:1625–1631.
   PubMed Web of Science ®Google Scholar
• Scotte F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005;23:4424–4429.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, Ribi K, Surber C et al. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08) Breast 2014;23:244–249.
   Google Scholar
• Grenier N, Lebel V, Gill M, et al. Nursing support program to decrease or prevent side effects of pegylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (REOC). Proc Am Soc Clin Oncol 2005;23(No16S,Part I of II):8198 [abstract].
   PubMed Web of Science ®Google Scholar